# Delayed diagnosis of Shwachman diamond syndrome with short telomeres and a review of cases in Asia 

Shin Yeu Ong ${ }^{\mathrm{a}}$, Shao-Tzu Li ${ }^{\mathrm{b}}$, Gee Chuan Wong ${ }^{\mathrm{a}}$, Aloysius Yew Leng $\mathrm{Ho}^{\text {a }}$, Chandramouli Nagarajan ${ }^{\text {a }}$, Joanne Ngeow ${ }^{\text {b,c,* }}$<br>${ }^{\text {a }}$ Department of Haematology, Singapore General Hospital, Singapore, Singapore<br>${ }^{\text {b }}$ Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre Singapore, Singapore<br>${ }^{\mathrm{c}}$ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

## ARTICLE INFO

## Keywords:

Shwachman diamond syndrome
Inherited bone marrow failure syndrome Telomere


#### Abstract

Inherited bone marrow failure syndrome (IBMFS) including Shwachman Diamond Syndrome (SDS) can present initially to the hematologist with myelodysplastic syndrome (MDS). Accurate diagnosis affects choice of chemotherapy, donor selection, and transplant conditioning. We report a case of delayed diagnosis of SDS in a family with another child with aplastic anemia, and review reported cases of SDS in Asia. This highlights the gap in identifying inherited bone marrow failure syndromes in adults with hematologic malignancies.


## 1. Introduction

SDS is an autosomal recessive disease characterised classically by exocrine pancreatic insufficiency and chronic neutropenia, but considerable phenotypic variation has been described even among siblings. In $90 \%$ of cases, SDS is caused by mutations in the Shwachman-BodianDiamond syndrome ( $S B D S$ ) gene that produces a protein with critical roles in ribosome biogenesis, mitotic spindle stabilization, and normal chromosomal segregation. While many pathogenic variants in the SBDS gene have been described, no correlation has been found between genotype and phenotype [1]. Three other causal SDS genes, DNAJC21, EFL1, and SRP54 have been reported. These genes have roles in the assembly of ribosomal subunits, the ribosomal subunit maturation, and ribosomal biogenesis respectively [2]. The epidemiology of SDS in Asia is not well studied and we performed a comprehensive review of reported cases to understand the clinical features and genetic variants here. A total of 65 cases have been described, most of which are from Japan. Those with clinical data are summarized in Table 1 [3-13]. Similar to previous reports, clinical manifestations including hematological abnormalities, pancreatic dysfunction, and short stature were common. The reported genetic mutations affecting patients in Asia were similar to their Western counterparts.

Individuals with SDS are at increased risk for developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Our review identified case reports of three patients who presented with MDS or AML without a prior diagnosis of SDS in Asia [9,14,15]. Similarly, SDS continues to be underdiagnosed internationally. Lindsley et al.
found that 7 of 241 young adults with MDS enrolled in the Center for International Blood and Marrow Transplant Research (CIMBTR) repository had SBDS mutations, and 5 of these patients did not have a diagnosis of SDS before transplant [16]. Other studies utilizing gene panel testing to screen for genetic predisposition to AML/MDS in young patients presenting with MDS identified SBDS gene mutations in 1 out of 110 patients and 2 out of 197 patients [17,18]. While underlying SDS is rare in young adults presenting with MDS/AML, the growing use of next-generation sequencing technologies may facilitate identification.

## 2. Case report

Our patient was a 19 year old male patient who presented with a onemonth history of fever, dyspnea, and skin abscesses. His full blood count showed pancytopenia and $14 \%$ blasts. Bone marrow aspirate was markedly hypocellular (10\% cellularity) with features of dyserythropoiesis and dysmegakaryopoiesis and 3\% blasts (Fig. 1). Flow cytometry detected $2.8 \%$ blasts that are CD34 + partial CD117 + and CD33+. Trephine was markedly hypocellular with rare hypolobated megakaryocytes and 8\% CD117+CD34+ myeloblasts. Cytogenetics with bone marrow karyotype showed a complex monosomal karyotype as follows, 42-45,XY,add(5)(q15),add(5)(q31),add(6)(q13), $\operatorname{der}(8) i n s(8 ; ?)$ (q13;?), $\operatorname{del}(9)(q 21 q 22), \operatorname{dic}(14 ; 22)(p 11.2 ; p 12), \operatorname{tas}(21 ; 16)(q 22.3 ; p 13.3)$, $\operatorname{add}(17)(\mathrm{q} 21),-18,-21,+\operatorname{der}(?) \mathrm{t}(? ; 8)(? ; q 13),+\mathrm{r},+1-2 \operatorname{mar}[\mathrm{cp} 21]$. These findings were compatible with primary hypocellular MDS or IBMFS evolving into MDS.

Physical examination revealed a relatively small head (3rd

[^0]Table 1
Cases of Shwachman-diamond syndrome reported in Asia.

| Country | Sex | Age at diagnosis | Pancreatic insufficiency | Hematological abnormalities | Skeletal abnormalities | Height (SD) | Body weight (SD) | SBDS mutations | Status at reporting |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Japan | M | 3 mo | + | Pancytopenia | - | $-2.1$ | -1 | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | NA |
| Japan | F | 8 y | + | Pancytopenia | + | -2 | -1.5 | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | NA |
| Japan | F | 5 mo | + | Pancytopenia | - | -3 | -2 | $428 \mathrm{C}>\mathrm{G} / 258+2 \mathrm{~T}>\mathrm{C}$ | NA |
| Japan | M | 1 mo | + | Pancytopenia | - | -3 | -1.8 | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | NA |
| Japan | M | 12 y | + | Thrombocytopenia | - | -3 | -1 | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | NA |
| Japan | F | 5 y | + | Pancytopenia | + | -2.9 | -1.4 | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | NA |
| Japan | M | 2 mo | + | Pancytopenia | + | -2 | NA | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | NA |
| Japan | M | 8 y | + | Pancytopenia | - | -2 | -1.5 | $258+2 \mathrm{~T}>\mathrm{C} / 259-1 \mathrm{G}>\mathrm{A}$ | NA |
| Japan | M | 6 mo | + | Neutropenia | - | -3.1 | -2.1 | 183-184TA > CT/unknown | NA |
| Japan | M | 9 mo | + | Pancytopenia | - | -3.6 | -3.4 | 183-184TA > CT $/ 258+2 \mathrm{~T}>\mathrm{C}$ | NA |
| Japan | M | 6 mo | + | AML | + | -4.8 | -1.8 | $258+2 \mathrm{~T}>\mathrm{C} / 292-295 d$ dAAAG | Alive |
| Japan | M | 2 y | + | MDS- > AML | + | -2.8 | -1.8 | 258+2T > C/unknown | Dead |
| Japan | M | 1 mo | + | MDS- > AML | + | -2.3 | -1.4 | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | Dead |
| Japan | M | 4y | + | Pancytopenia | + | -1.3 | -1.1 | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | Alive |
| Japan | M | 2 y | $+$ | - | - | -3.5 | -1.7 | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | Alive |
| Japan | F | 8 y | $+$ | Pancytopenia | + | -3.5 | -1.3 | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | Alive |
| Japan | M | 5 mo | $+$ | Pancytopenia | - | -3 | -3.5 | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | Alive |
| Japan | F | 15 mo | $+$ | Neutropenia | - | -5.2 | -6.6 | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | Dead |
| Japan | F | 2y7mo | + | MDS | - | -1.2 | -2.3 | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | Alive |
| Japan | F | 4 mo | - | Neutropenia | + | -7.5 | NA | $79 \mathrm{~T}>\mathrm{C} / 183 \mathrm{TA}>\mathrm{CT}$ | Alive |
| Korea | F | 3 y 6 mo | + | Neutropenia | + | $<3 \%$ | < $3 \%$ | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | Alive |
| Korea | M | 13 y 9 mo | + | Bicytopenia (WBC/PLT) | + | <3\% | <3\% | 183-184TA > CT/258 + 2 T > C | Alive |
| Korea | M | 15 y 6 mo | + | bicytopenia (WBC/PLT) | + | 3\% | 10\% | $258+2 \mathrm{~T}>\mathrm{C}$ homozygous | Alive |
| India | M | 4 y | + | Pancytopenia | - | NA | NA | $258+2 \mathrm{~T}>\mathrm{C}$ homozygous | Dead |
| China | M | 8 y | + | Bicytopenia (WBC/RBC) | + | < $3 \%$ | 3\% | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | Alive |
| China | M | 1y3mo | + | Neutropenia | + | NA | < $3 \%$ | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | Alive |
| China | F | 6 mo | $+$ | Pancytopenia | + | NA | NA | 183-184TA $>\mathrm{CT} / 258+2 \mathrm{~T}>\mathrm{C}$ | Alive |

[^1]
# https://daneshyari.com/en/article/8453540 

Download Persian Version:

## https://daneshyari.com/article/8453540

## Daneshyari.com


[^0]:    * Corresponding author.

    E-mail address: joanne.ngeow.y.y@singhealth.com.sg (J. Ngeow).
    https://doi.org/10.1016/j.lrr.2018.04.002
    Received 9 January 2018; Received in revised form 2 April 2018; Accepted 7 April 2018
    Available online 09 April 2018
    2213-0489/ © 2018 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).

[^1]:     myelodysplastic syndrome; AML, acute myeloid leukemia.

